hESC derived Cytiva™ Cardiomyocytes for Drug Safety Testing
This presentation demonstrates how hESC derived cardiomyocytes can be a powerful approach to assessing cardiac drug liabilities. Nick Thomas describes how hESC derived Cytiva Cardiomyocytes:
- are a valid model of cardiomyocytes from the human heart
- are compatible with assays routinely used for testing cardiotoxicity
- together with high-content assays and analysis, can indicate the mechanism of toxicity of drug compounds
Nick Thomas PhD
Dr. Nick Thomas is Principal Scientist at GE Healthcare Life Sciences. In a twenty-seven year career he is the inventor or co-inventor of over 60 patents covering a wide range of technologies from microfabrication to molecular and cellular sensors.
* = required.